AI summary by TwinMind
The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug | WSJ
The Wall Street Journal
6m 10s
Alzheimer's Disease Overview
- Time lapse shows normal brain vs Alzheimer's brain over 6 years
- Disease kills 120,000+ people annually in US
- Researchers spent 3+ decades trying to cure
- Current drugs only alleviate symptoms, don't slow disease progression
- Biogen's Aduhelm (aducanumab) aims to be first drug to slow progression
Alzheimer's Disease Mechanism
- Attacks neurons controlling movement, senses, memory, thinking
- Communication between neurons interrupted, cells die
- Two key biomarkers: amyloid plaques and tau tangles
- Normal proteins (amyloid precursor protein, tau protein) needed for brain function
- In Alzheimer's: proteins modified, aggregate/clump together
- Beta-amyloid plaques accumulate throughout brain, block cell communication
- Tau tangles build up inside neurons, block nutrient pathways
- Plaques and tangles kill brain cells permanently
Aduhelm Drug Mechanism
- Generic name: aducanumab
- Targets amyloid plaques using monoclonal antibodies
- Antibodies designed in lab, modeled on natural antibodies from Alzheimer's-resistant people
- Process:
- Antibodies injected, travel to brain via bloodstream
- Latch onto plaques
- Attract microglia (natural scavenging cells)
- Microglia digest plaque material
- Amyloid cleared through blood vessels
- Theory: removing plaques slows/stops accumulation, delays brain cell death
Clinical Trial Controversy (Since 2019)
- Biogen ran two large Phase 3 trials
- Shut down prematurely - thought trials wouldn't work
- Later pooled analysis showed different results when examined separately
- Both trials: effective at reducing brain plaque
- Only one trial: showed effect on patient decline (22% slowing of symptom progression)
- Joseph Walker (biotech reporter) covered controversial development
FDA Approval Decision
- Granted accelerated approval despite incomplete evidence
- Drug not fully proven but showed promising results
- Can be prescribed while additional study conducted
- FDA cited urgent need for treatments
- Many doctors question insufficient evidence of benefits/safety
Safety Concerns
- Side effects from amyloid removal:
- Brain swelling
- Small brain bleeds
- Contested theory: removing amyloid alone will slow Alzheimer's
- Some consider approval premature based on unproven amyloid hypothesis
Cost and Access Issues
- Initial price: $56,000 per year for average person
- Sticker shock caused insurer coverage limitations
- Price cut in half December 2021
- Many health insurers and doctors reluctant to cover/prescribe
- Creates uncertainty around drug adoption
Future Outlook
- Other companies testing amyloid-targeting treatments
- Dr. Paul Aisen (Biogen consultant): most encouraging results in 30 years of research
- Work stimulated and excited the field despite controversy
- Currently approved only for early-stage patients
- Biogen conducting confirmatory trial
- Final results likely years away
